Introduction
In vertebrates Galectins are a family of proteins presently known to comprise of 10 polypeptides (Colnot et al., 1996; Cooper and Barondes, 1999; Kasai and Hirabayashi, 1996) encoded by distinct genes. These proteins are structurally related, containing conserved domains that give them the ability to recognize and bind glycoproteins having b-galactoside side-chain residues (Rini, 1995) . Within the galectin gene family, further sub-classi®cation can be made by distinguishing between galectins containing a single carbohydrate recognition domain (CRD) termed the prototype galectins, a two CRD containing polypeptide where each domain is separated by a linker sequence called the tandem repeat galectins and a chimeric-type protein wherein an unrelated aminoterminal domain is linked to a CRD (Cooper and Barondes, 1999; . Galectins appear to have originated at a fairly early time during evolution since they occur in marine sponges and fungi (Arata et al., 1997; Cooper et al., 1997; Greenhalgh et al., 1999; Wagner-Hulsmann et al., 1996) . Functionally, the galectins as a family have been associated with diverse phenomena in every cellular compartment, including cell surface or extracellular roles in adhesion (Inohara and Raz, 1995; Kaltner and Stierstorfer, 1998; Lotan et al., 1994) , cell to cell recognition and signaling (Inohara and Raz, 1995) , intracellular association with speci®c organelles and within the nucleus in association with components of the splicing machinery and with mRNA splicing (Dagher et al., 1995; Vyakarnam et al., 1997 Vyakarnam et al., , 1998 . Incompletely de®ned functional associations of several galectins have also been reported in embryonal development, signal transduction, dierentiation (Lu et al., 1998; Lu and Lotan, 1999) , transformation (Bresalier et al., 1997; Ellerhorst et al., 1999; Gillenwater et al., 1996) , tumor suppression, metastasis and the immune response (Akahani et al., 1997; Barondes et al., 1994; Bresalier et al., 1996 Bresalier et al., , 1997 Chammas et al., 1996; Colnot et al., 1996; Cortegano et al., 1998; Hebert et al., 1996; Hsu et al., 1999; Remmelink et al., 1999) . At the present time, the normal physiological roles of galectins remain substantially unde®ned and considerable eort is being devoted towards understanding their biological relevance in speci®c cellular contexts.
Mammalian galectin nomenclature broadly re¯ects the temporal order of discovery, Galectin -1 and -3, therefore ®nd the highest degree of representation in the literature. Galectins containing tandemly repeated CRD domains, including Galectins -4, -6, -8 and -9, remain relatively uncharacterized. It is believed that this type of galectin arose by duplication and subsequent divergence of relevant exons from single CRD containing genes during evolution. An average of 30% amino acid identity and conserved structural homology between the two CRDs substantiate this notion (Hadari et al., 1995; Wada and Kanwar, 1997) . Galectins in general, have the propensity to form higher order multimers, usually as a result of binding to glycoconjugate receptors. In the native unbound state, single CRD galectins (Galectins -1 and -2) exist as dimers while Galectins -3, -7 and -10 form higher order aggregates only in the presence of receptors with multiple binding sites (Arata et al., 1997; Chammas et al., 1996; Cho and Cummings, 1995a,b; Kaltner and Stierstorfer, 1998) . Double CRD containing molecules, through the ability of each CRD to recognize distinct glycoconjugates, are thought to have the additional capability of acting as hetero-bifunctional crosslinking agents and therefore have a broadened range of interactive capacity (Arata et al., 1997; Gitt et al., 1998a; Kaltner and Stierstorfer, 1998) . This implies that a further level of complexity could exist in the range of interactions that tandem repeat type galectins can participate.
PCTA-1 was isolated in a cloning project to identify molecules speci®cally expressed on the surface of prostate cancer cells. This approach involved an immunological subtraction scheme, surface epitopemasking (SEM), in which polyclonal antibodies produced against unmodi®ed cloned rat embryo ®broblast cells were used to coat the surface of genetically modi®ed cells transformed using high molecular weight DNA from a human prostate cancer cell line, LNCaP. The coated cells were used to raise monoclonal antibodies which recognize prostate cancer speci®c surface epitopes (Shen et al., 1994) . Expression screening of a cDNA library to identify clones encoding the antigen recognized by the respective antibody was performed to determine the identity of the reactive antigen. One of the several monoclonal antibodies isolated in the course of this screen, designated as Pro 1.5, speci®cally recognized a cDNA clone expressing a protein having 81% amino acid sequence homology to a sequence present in the databases at that time, namely rat galectin-8 . Based on this homology, it appeared that the isolated sequence was a human tumor homolog of the rat sequence. Antibody studies and RT ± PCR based expression analysis in prostate cancer cell lines and tissue samples, indicated an association of PCTA-1 expression with prostate carcinoma . In the present study we describe several independent approaches designed to elucidate the cellular function of this protein and to determine its potential role in carcinogenesis. These include analysis of the genomic structure of the encoding locus to determine the nature and relationship between multiple species of PCTA-1 mRNA observed in normal and transformed cells and tissues, now determined to be based on a combination of alternately spliced and dierentially polyadenylated variants. To understand the potential role of PCTA-1 in carcinogenesis, studies determining tissue distribution, intracellular localization and the phenotypic eects of overexpression in cells have also been performed.
Results
The PCTA-1 gene localizes to a genomic region associated with familial prostate cancer To determine if the genomic locus encoding PCTA-1 was located within a region associated with human disease, PCR with speci®c cDNA primers 177 bp apart was performed on a rodent-human chromosome hybrid panel. Hybrids containing chromosome 1q scored positive in this screen (Figure 1a,b) . A Stanford RH panel (Research Genetics) was used to re®ne the initial mapping data. Analysis on the Stanford rh server showed linkage to two markers (with LOD score greater than 6). DIS235 and DIS446 were linked to PCTA-1 at distances of 16.98 cR-8000 and 33.23 cR-8000, respectively. This data was con®rmed after testing the Gene bridge radiation hybrid DNAs (Research Genetics). The WICGR mapping server found very close linkage to WI-9317 (DIS2421) and WI-6955 (DIS2383). Thus, PCTA-1 maps to the chromosome region 1q42-43, where these linked markers have been localized (Figure 1b) . This locus has been identi®ed in a recent European study (Berthon et al., 1998) to contain a predisposing gene for early-onset prostate cancer based on analyses of several families with a recorded genetic predisposition for the disease.
Genomic structure of PCTA-1
Screening of a bacterial arti®cial chromosome human genomic library (Genome Systems Inc.) yielded two overlapping clones that spanned the entire PCTA-1 locus. Clones were sequenced to determine the exon/ intron junctions using appropriate primers and alignment to the cDNA sequence. The results of this analysis (Figure 2 ) showed that the locus was comprised of eight constitutively present exons (exons 2 ± 9). Two additional exons (7' and 7'') are represented only in a sub-population of PCTA-1 message due to alternative splicing. The two exons at the extremities (exons 1 and 10) are present as partial or complete entities in the mature message due to internal processing.
The 5' most exon is present in the mature transcript either as a single 828 nt unit or is processed internally (Figure 3a) to give a 488 nt product. We were initially unaware of the smaller processed transcript since our RT ± PCR analyses with prostate cancer cell RNA only detected the larger product. Primer extension analysis ( Figure 3b ) using a primer close to the 3' extremity of the exon yielded two extension products implying the possibility of two transcription start sites. Sequence analysis of the exon and a database search determined that transcription initiates at a single site (Figure 3a , +1`C' residue) and the two products represent the non-truncated or additionally processed forms of the ®rst exon. There is a TATA-box consensus sequence present 43 bp upstream of the identi®ed transcription start site indicating that the promoter falls into the TATA-containing class. Database searches identi®ed three sequences with 5' regions identical to the shorter processed form of exon 1 (Accession numbers AF074000, AF074001 and AF074002). These entries correspond to dierentially processed forms of a cDNA closely related to PCTA-1, designated Po66 and isolated from human lung squamous carcinoma (Bassen et al., 1999) . It is possible that the predominant mRNA species vary depending on the tissue source of isolation, though we can not rule out the possibility that our conditions for RT ± PCR caused a bias toward detection of the larger isoform since both are clearly detected in primer extension analysis using prostate derived RNA.
There is an overall conservation of structure for the exons encoding the carbohydrate binding domains of (Figure 2 ) compared to that observed for the other galectins. In general, genomic loci encoding galectin CRDs comprise of a 3-exon unit implying a common evolutionary origin (Gitt et al., 1998b; Hadari et al., 1995) . In the tandem repeat galectins, each of two separate CRDs are encoded by two such 3-exon units separated by exons for the intervening linker region, an architecture seemingly conserved in the PCTA-1 locus (Figure 2 , exons 3 ± 5 for CRD-1 and 8 ± 10 for CRD-2). The linker region in Galectin-6 is spread over two exons as initially seemed to be the case in PCTA-1. However, based on alignment of sequences reported in AF074001 and AF074002 with our BAC derived genomic sequence, two additional exons (Figure 2 , exons 7' and 7'') were discovered. ESTs in current databases with identity to alternate exons 1 and 2 (Figure 2, 7' and 7'', Figure 6, ALT1 and ALT2) are present at frequency of one and four independent cDNAs respectively, compared to 42 independently reported sequences for the PCTA-1 isoform wherein these elements are absent. It therefore seems that these alternately spliced exons ( Figure 6 , ALT1 and ALT2) constitute relatively minor proportions of total PCTA-1 message, with the major form present in cells most likely containing exon 7 directly spliced to exon 8. We have therefore preferred to designate these alternatively spliced exons as 7' and 7''. Conceptual translation of the ORF without the alternate exons or with each one individually or both linked together in tandem give rise to proteins related to PCTA-1 (i.e. the reading frame of the PCTA-1 ORF continues to be maintained) other than an extended linker region. To our knowledge this is the ®rst instance of galectin peptide modi®cation of this nature and is likely to impact on function and carbohydrate binding capacity since the two CRD will be spaced further apart as a result of the expanded linker region contributed by inclusion of one or both alternative exons.
The lower panel in Figure 2 show the exonic part of the splice junction boundaries of all the constitutively present exons and the 5' UTR. All but one of the exons (exon 7'') are¯anked by consensus splice donor and acceptor site GT : AG sites. The sequence of the two alternate exons that have been previously reported in AF074001 and AF074002 are Alternate exon 1 (7'): 5'-CCT AGT AAT AGA GGA GGA GAC ATT TCT AAA ATC GCA CCC AGA ACT GTC TAC ACC AAG AGC AAA GAT TCG ACT GTC AAT CAC ACT TTG ACT TGC ACC AAA ATA CCA CCT ATG AAC TAT GTG TCA AAG-3' Alternate exon 2 (7') 5'-CAG ACT GTC TCT CCC CTC CTG GGA TTT ACA GGG TCA TGG CTC TGA AAC ATT CTG TAG (Position 55,56) TGT TCT TTG GAC ACG AGT TTT CCC TGG AGA TCG CTT TCT GCA GGC CTA TTG GTC CTG ACT GTG GCT TCT TTT CAG-3'
Alternate exon 1 has consensus splice donor and acceptor sites and is likely to be included or excluded Figure 3 Transcription start site and primer extension analysis. Primer extension analysis using an antisense extension primer (a, in light gray type, underlined) generated two extension products (b, lane 1). Shown is the +1 transcription initiation site and putativè TATA-box' promoter element based on the position of extension primer and size of the extension products. An alternatively processed form of the 5' UTR, reported under GenBank Accession numbers AF074000, AF074001 and AF074002 (smaller product in b, lane 1) is generated by splicing the intervening sequences between positions 572 ± 914 (Splice donor and acceptor sites in bold). As discussed in the text, using RT ± PCR analyses with prostate cancer cell RNA (PC-3 total RNA, b lane 1) we primarily detected the unprocessed longer form of the UTR. Speci®city of the extension product was determined by using yeast total RNA as negative control (b, lane 2). Size and sequence of the transcription start site was determined by running sequencing reactions with the primer extension primer (not shown) and end-labeled commercial size standard (b, lane M) depending on whether it is by-passed or not by the splicing machinery. Alternate exon 2 as originally reported (AF074002) has a 5'GG instead of AG splice consensus sequence. Three additional C residues diering from those reported in AF074002 were observed in our analyses, (`Cs' in above sequence; con®rmed by several sequencing passes over the same genomic region and also present in EST database sequences). In addition, alternate exon 2 (Figure 2 , exon 7'') is physically contiguous with exon 8 in genomic DNA. The last codon in this exon codes for a glutamine residue (CAG). It appears that AG-residues which are part of the last codon (CAG) of exon 7'' doubles as a 5' splice consensus site for exon 8, to join the 3' end of exons 7 or 7' to exon 8. It appears that the splicing machinery recognizes the AG sequence at the 5' end of exon 7'' (positions 55 and 56), at a much lower frequency, and includes it in combination with exon 8 as a single exonic unit. Current conceptual translation of Alternate Exon 2 with the additional C residues (see sequence above) demonstrate that the ORF can only be maintained if splicing occurs at position 57 and not at the originally indicated sequence (AF074002). Based on our sequence analyses and existence of EST sequences in the databases, it appears that the region around this exon is error prone with respect to splicing. Many EST sequences and the sequence reported in AF074002 seem to be products of partial mRNA processing leaving behind parts of unor incorrectly spliced intronic sequences. Based on the frequency of occurrence (in the EST database) it appears that transcripts containing these alternate exons are much less frequent than transcripts excluding them. At the present time it is unclear as to what signals or events govern selective occurrence of one type of processing event over the other. It also appears that many dierent isoforms are expressed in varying amounts by a given cell population and possibly within the same cell at all times (see next section).
The 3' UTR of PCTA-1 is encoded by dierential processing of a single large 4352 bp exon. This exon contains (Figure 2 , exon 10) 147 bp of coding sequence followed by the stop codon and remaining part comprising UTR sequence. The UTR is processed by the 3' processing polyadenylation machinery to generate three dierentially polyadenylated species of PCTA-1 mRNA having UTR lengths of 126, 1103 and 4217 bp respectively, when calculated from the stop codon. It is interesting to note that the polyadenylation consensus sequence AAUAAA is not present at any of the three sites of processing (putative signals for polyadenylation at the respective sites matching most closely to the consensus, based on position and sequence are TTAAAAT, ATTAAAA and AATGTGAAA, respectively). The location of 3' termini was derived from direct sequence analysis of oligo-dT primed RT ± PCR products and sequence comparisons with database information available at the time of submission. It is possible that additional 3' isoforms may be isolated in the future following analysis of RNA derived from tissues other than prostate or due to altered physiological status of cells by various treatments. The original 3.8 kb message reported for PCTA-1 appears to have been primed from a stretch of A-residues present in genomic DNA encoding the 3' UTR and likely represents oligo-dT priming from a site that is not a genuine poly-A tail.
The PCTA-1 locus encodes multiple mRNA species that are differentially spliced and/or differ in the site of polyadenylation Northern blot analyses using a probe containing the ORF of PCTA-1 detected three major species of RNA having sizes corresponding to approximately 1.6, 2.6, and 6.0 kb. These species were detected irrespective of whether total RNA or enriched polyadenylated fractions were used (Figures 4 and 5) . PCTA-1 displayed a ubiquitous pattern of expression in all human tissues analysed (Figure 4 , upper panel, PCTA-1 ORF probe). Relatively high expression was seen in heart, placenta, liver, pancreas, spleen, testis, ovary, spinal cord, lymph node, trachea and adrenal gland. Intermediate expression was observed in lung, kidney, prostate, peripheral blood lymphocytes, stomach and thyroid. Low expression occurred in whole brain, skeletal muscle, thymus, small intestine, colon and bone marrow. Due to partial homology at the nucleotide level between the dierent galectins, there was concern that use of an ORF probe (PCR product spanning ATG to stop codon) might cross hybridize to related and more highly expressed galectin RNAs. A galectin-3 ORF cDNA (PCR product spanning ATG to stop codon) was used to reprobe the multiple tissue Northern blot (Figure 4 , lower panel, Galectin-3 ORF probe). An anticipated signal of 1.3 kb for galectin-3 was dissimilar in size, intensity and tissue distribution from that obtained with PCTA-1, indicating that probes and hybridization conditions used in these studies distinguished between related sequences. Overall, the PCTA-1 signal and therefore message abundance seemed to be lower than Galectin-3 (the PCTA-1 blots were exposed twice as long) and this was true for several other experiments ( Figure 5 and data not shown) where PCTA-1 signals were only visible after relatively longer exposures compared to other genes probed on the same blot. In fact, it was not possible to detect PCTA-1 RNA by reprobing a previously used blot, pointing towards overall rareness of message abundance of PCTA-1.A PCR ampli®ed probe corresponding to the 3' UTR sequence beyond the poly-A site of 1.6 and 2.6 transcripts , detected only the 6 kb product (Figure 4 , lanes 24 ± 31) con®rming that the relationship between the transcripts detected by the ORF probe is in part due to diering 3' UTR lengths as described in the above sections and Figure 6 .
From results obtained with the Northern blots containing normal human tissue derived RNA it is clear that PCTA-1 is expressed at detectable levels in many normal tissues (Figure 4 ). To determine if there was any correlation between expression status and cellular transformation, Northern blot analyses were performed with prostate cancer and melanoma cell line derived RNA ( Figure 5 ). Two aspects of PCTA-1 expression were analysed in these series of experiments. First, to determine whether the level of PCTA-1 expression was enhanced as a consequence of transformation. Secondly to observe if the presence of speci®c isoforms was correlated with transformed cells. In addition to detecting the three major transcripts described above (normal tissue derived poly-A RNA), we were able to consistently observe two additional bands of around 4.5 and 9.0 kb ( Figure 5 , upper and lower panels, ®rst and third arrowheads from top) with total RNA from prostate or melanoma cell lines as well as normal human prostate tissue RNA (Clontech) using the ORF probe. The origin of the 9.0 kb transcript is presently unclear and attempts to RT ± PCR this sequence using oligo-dT and known 3' UTR primers have not been successful. After considering all the theoretically possible isoforms (Figure 6 ), it is also dicult to account for a 4.5 kb transcript. Our working hypothesis is that these additional species might represent partially processed forms of the nascent transcript since total RNA was used in these experiments. These two forms are not detectable with polyA-RNA (Figure 4 ) and further analysis is presently underway. It is apparent that the three larger species (4.5 ± 9.0 kb) contain the 3' UTR region extending beyond the terminus of the 2.6 kb transcript since they hybridize to a probe in that region ( Figure 5 , 3' UTR panels). It appears that the alternate exons (Figure 2 , exons 7' and 7'') are present in at least a subpopulation of PCTA-1 transcripts since positive signals were obtained using speci®c PCR generated probes containing only these sequences. It is possible that these alternate exons and corresponding larger forms of protein, have a higher prevalence in transformed tissues ( Figure 5 , panels ALT1 and ATL2, compare lanes D and P to N) (Bassen et al., 1999) . However, the low abundance of ALT1 transcripts in LNCaP prostate cancer samples argues against such a generalization. The only unchanging aspect of PCTA-1 expression has been a complete lack of consistency of isoform expression in a given cell type. For reasons that are presently unclear, there is apparently a random shift in the overall composition and individual abundance of a given isoform within the same cell type harvested at dierent times. We have attempted to determine if growth conditions in¯uence these changes by harvesting RNA from cells grown at high, median and low cell densities (data not shown) but this does not have any apparent eect in causing selective expression of a given isoform. Results as they stand at the present time seem to indicate that regulation of the composition and abundance of isoforms appears to be stochastic in nature. The one reproducible pattern has been an apparent higher overall expression level of the sum total of all isoforms in cell lines that have the capacity to form metastatic tumors in nude mice, namely the PC-3 prostate cancer and C8161 melanoma cell lines, compared to expression levels in normal prostate or non-metastatic cell lines ( Figure 5 , compare lanes P to others in the upper panels and C to others in lower panels). This phenomenon was observed in several independent batches of RNA and further conformational studies are underway. The predicted number of possible permutations of dierent variable elements is the PCTA-1 gene transcription unit stands at 18 (Figure 6 , right hand column). Many of these isoforms may not be resolved as separate species during electrophoresis depending on gel running conditions and abundance (e.g. 1.6 ± 1.79, 2.011 ± 2.143 2.7 ± 2.9 and 5.7 ± 6.1 kb species) while others have at the present time not been observed (2.9 ± 3.1 kb species).
Intracellular localization and phenotypic effect of overexpression
Intracellular location can provide important clues in discerning the biological role of a protein of Figure 4 Human tissue mRNA expression pattern and variant forms of PCTA-1 mRNA compared to human galectin-3 expression. Commercial multiple tissue Northern blots (Clontech) were probed sequentially with radiolabeled PCTA-1 ORF probe (upper panel, lanes 1 ± 23), 3' UTR probe (upper panel, lanes 24 ± 31) and human galectin-3 ORF probe (lower panel, lanes 1 ± 23). Lanes 1 ± 8 (upper and lower panels) contain mRNA from 1 ± heart; 2 ± whole brain; 3 ± placenta; 4 ± lung; 5 ± liver; 6 ± skeletal muscle; 7 ± kidney; 8 ± pancreas. Lanes 9 ± 16 upper and lower panels and 24 ± 31 upper panel contain, mRNA from, 9, 24 ± spleen; 10, 25 ± thymus; 11, 26 ± prostate; 12, 27 ± testis; 13, 28 ± ovary; 14, 29 ± small intestine; 15, 30 ± colon; 16, 31 ± peripheral blood lymphocytes. Lanes 17 ± 23 (upper and lower panels) contain mRNA from 17 ± stomach; 18 ± thyroid; 19 ± spinal cord; 20 ± lymph node; 21 ± trachea, 22 ± adrenal gland; 23 ± bone marrow respectively undetermined function. Eukaryotic plasmid expression vectors were constructed to express a GFP/PCTA-1 fusion protein. An advantage of using this type of analysis is that expression may be observed in live un®xed cells avoiding potential artifacts generated by sample ®xation protocols. Expression of the correct sized GFP PCTA-1 fusion protein was determined by Western blotting of whole cell extracts from HeLa cells transiently transfected with the GFP PCTA-1 expression vector (Figure 7a ). Live un®xed samples transfected in parallel were observed for expression and intracellular localization of PCTA-1 (Figure 7b ) bȳ uorescence microscopy. PCTA-1 expression was extra-nuclear, expression was observed only in the cytoplasm (as compared to wild-type GPF vector control, which was evenly distributed in both compartments, data not shown). Expression was however not uniformly spread throughout the cytoplasm and showed a micro-clustering pattern reminiscent of that seen with proteins associated with mitochondria, the golgi or transgolgi membranes and observed for some other Galectins (Bassen et al., 1999; Hadj Sahraoui et al., 1996; Lutomski et al., 1997; Maldonado et al., 1999; Maquoi et al., 1997; Sara®an et al., 1998; .
Eukaryotic expression vectors expressing the fulllength ORF or a deletion of the second CRD (qCR1) were constructed, transfected into HeLa cells and stably expressing clones isolated by drug selection. These clones were analysed by Northern blot to con®rm continued stable expression of PCTA-1 (not shown). Soft-agar colony formation assays were performed with stable cell lines expressing full-length, truncated and vector control cells. Continued stable over-expression of PCTA-1 in cells inhibited the ability to form colonies in soft agar by an average of 40% compared to HeLa vector control (Figure 8a ) while cells expressing the truncated version of PCTA-1 displayed around 30% enhanced rate of soft agar colony formation. The ability of full length PCTA-1 to inhibit colony formation was independently con®rmed by infecting DU-145 cells with a non-replicating Adenovirus vector expressing full-length PCTA-1. While the empty Adenovirus control vector inhibited colony forming ability of these cells by 50%, probably due to non-speci®c toxicity, no colonies were observed in cells infected with a vector expressing PCTA-1 i.e. an inhibition of 100% was observed. Adenoviruses have a close to 100% rate of infectivity in a cell population and also produce high levels of gene expression in a short span of time (10 ± 100-fold increase of expression within 24 h post-infection), the dynamics of expression between stably expressing and virally transduced cells will therefore be dierent. Figure 5 Multiple forms of PCTA-1 message in prostate and melanoma. Total RNA from human prostate cancer cell lines DU145 (D), LNCaP (L), PC-3 (P) and commercial (Clontech) normal prostate (N) was analysed by Northern blot using region speci®c cDNA probes containing the ORF, alternate exon 1 (ALT1), alternate exon 2 (ALT2) and 3' UTR. Four identical sets of RNA were run in parallel on the same gel, transferred and strips cut and individually probed for each set. A representative ethidium bromide (EtBr) stained RNA gel before transfer is shown to indicate approximately equivalent RNA was analysed from each source. A commercial RNA standard (Life Technologies, Lane M) was used to determine size of signal obtained after autoradiographic exposure. Total RNA from human melanoma cell lines C8161 (C) and HO-1 (H) with normal prostate RNA (N) as control was analysed by Northern blot using region speci®c cDNA probes containing the ORF and 3' UTR. The ethidium bromide (EtBr) stained RNA gel before transfer is shown to indicate approximately equivalent RNA was analysed from each source. A commercial RNA standard (Life Technologies, Lane M) was used to determine size of signal obtained after autoradiographic exposure
Discussion
Some animal Galectins have been isolated and puri®ed by biochemical procedures as molecules having hemagglutinin or other glyco-binding activity e.g. Galectins-1 and -3 (Blaser et al., 1998; Chadli et al., 1997; Iglesias et al., 1998; Puch and Bhavanandan, 1999) . Others have been isolated in screens designed to identify molecules associated with speci®c biological phenomena such as carcinogenesis or dierentiation, employing screens using expression cloning approaches e.g. Galectin-5, rat Galectin-8 and PCTA-1 (Gitt et al., 1998a (Gitt et al., , 1995 Hadari et al., 1995; Su et al., 1996) . PCTA-1 was identi®ed in two independent carcinoma related screens involving prostate cancer surface marker identi®cation and in a lung cancer cDNA library expression screen (Bassen et al., 1999) , respectively. It may be worth noting that the isolation of rat Galectin-8 occurred by chance during an expression screen with insulin-receptor substrate-1 antibody that should not have recognized this completely unrelated protein (Hadari et al., 1995) . Our analysis with the Pro 1.5 antibody (Shen et al., 1994; Su et al., 1996) used to isolate PCTA-1 in the (Figure 3 ) is represented by two lightly ®lled-in adjoining rectangles (internally spliced short 5' UTR) as opposed to the full non-spliced 5' UTR (long form of 5' UTR). Since the ATG containing exon is also comprised of a small and invariant portion of 5' UTR sequence (Figure 2) , these have been shown together as a single unit, the bulk of which comprises the ORF. The variable forms of this unit contains either of three possibilities, inclusion of two additional exons which increases the length of the ORF and a third probably predominant form, lacking either alternate exon formed by direct splicing of exons 7 ± 8 (Figure 2) . The three dierentially processed 3' UTRs (dark shaded rectangles) make up the mature transcripts. The ®nal sizes of each possible transcript are indicated in the right hand column depending on which speci®c combination of elements (middle columns) are contained within them expression screen was however able to detect dierences in protein level in cell lines and tissue sections between normal versus malignantly transformed human prostate samples implying speci®city of recognition. An additional connection to prostate cancer was provided by chromosomal localization of PCTA-1 to the 1q42.2-43 region of the human genome, shown by a recent European study to contain a putative predisposing gene for prostate cancer (Berthon et al., 1998) . This region is distinct from the earlier predisposing locus thought to lie on 1q24-25. Other genes including poly ADP-ribose polymerase and RAB-4 (Ras-related GTP-binding protein) (Berthon et al., 1998) lie within this locus. It also harbors a fragile site (Feichtinger and Schmid, 1989) , replicationerror type-genetic instability locus (Murty et al., 1994) and was observed to translocate in glioblastomas (Li et al., 1995) . It seems more than coincidental that PCTA-1 is the only gene in this locus identi®ed in a prostate cancer speci®c screen. Further genetic and biochemical analyses presently underway should determine the nature and extent of PCTA-1 chromosomal location and association with prostate cancer.
The CRDs of galectins comprise of an approximately 135 amino acid domain, which in PCTA-1 is separated by the so-called linker region. In the case of every Galectin gene studied so far, the CRD is encoded by three exons (Gitt et al., 1998b; Hadari et al., 1995) , the middle one being most conserved and containing the codons encoding the sugar residue binding site. PCTA-1 is no exception in this respect, exons 3 ± 5 and 8 ± 10 contain the CRD encoding sequences. Comparable to the gene structure of Galectin-6, the linker region of PCTA-1 is encoded by two exons in the most prevalent mRNA species. The genomic organization of PCTA-1 varies from other Galectins including the other tandem repeat type (Galectins -4, -6 and -9) by alternate splicing of exons 7' and 7'' causing variation in the length of the linker region (Figure 2 ). These are alternatively spliced into the ORF to extend the linker region by 126 bp (43 aa), 75 bp (25 aa) or 201 bp (68 aa) depending on whether 7', 7'' or both combined together are spliced into the existing PCTA-1 ORF. Further work is needed to determine the consequences of the extended linker region, which could impact on the range of polysaccharides recognized by the dierent isoforms. Deletion of the N-terminal domain of Galectin-3 impacts on its cellular localization (Mehul and . The linker region of tandem type Galectins are not homologous to the Galectin-3 Nterminal domain and the precise functionality of the additional isoforms await the production of reagents that can detect them speci®cally.
A signi®cant extent of variation at the mRNA level also occurs at the 5' and 3' ends of the gene. Exon 1 is detectable in the mature transcript as an unspliced 828 bp or spliced 488 bp UTR region. Conformational analysis of this sequence for hairpin loops and other secondary conformations showed that a very high degree of stable secondary structure formation was possible (average free energy of 7100 Kcal) for both long and short forms of the 5' UTR. The 5' processing events were con®rmed by performing primer extension analyses (Figure 3b ) that detected two bands of approximately 750 and 415 nt. The single transcription start site indicated in Figure 3a is likely driven by a putative TATA-box containing promoter based on sequence homology and relative position of the relevant sequences. Parallels can be drawn between the predicted value of free energy seen in the PCTA-1 5' UTR and that observed for many growth regulatory genes (Willis, 1999) . It is hypothesized that 5' UTR secondary structure conformation acts as a further level of expression regulation by impeding passage of ribosomes and decreasing overall translatability of the mRNA (Willis, 1999) . Speci®c cellular translation enhancing factors, that might play a role in overcoming the apparent translation block of such mRNA have been partially characterized and dysregulated activity of such translational enhancers has been hypothesized to play a role in transformation. Though presently unproven, the intriguing possibility exists that PCTA-1 protein levels might be modulated using a strategy commonly used by cells to ®ne tune expression of growth modulators (Willis, 1999) .
Alternative sites of polyadenylation and associated processing give rise to the three major isoforms of mRNA visible on Northern blots with PCTA-1 cDNA speci®c probes. The alternatively processed 3' UTR is however transcribed from a single large exon 10. Commercial multiple tissue Northern blots made from polyadenylated RNA detected the three major species of transcripts of approximately 6.0, 2.6 and 1.6 kb ( Figure 4 , PCTA-1 ORF probe). The 2.6 and 1.6 kb transcripts are well represented in EST database sequences and has been independently con®rmed by our own RT ± PCR product sequence analysis. We reprobed one of the multiple tissue blots with a fragment speci®c for sequences downstream of the 3' end of the 2.6 kb transcript. Since this detected a single major band of 6 kb, it con®rmed the relationship between the three dierent transcripts as being alternately processed, truncated and polyadenylated variants of exon 10.
When total RNA was used in Northern blot analyses two more transcripts of around 4 and 9 kb were visible ( Figure 5 , i.e. Prostate and Melanoma ORF panels). Since these are not detectable using polyadenylated RNA they could represent processing intermediates of the primary transcript. We attempted to determine if any speci®c pattern of expression existed for given isoforms in a normal or transformed cellular background. At the RNA level, PCTA-1 was expressed in both normal tissue (Figure 4 , lanes 1 ± 31; Figure 5 , lane N) and transformed cell contexts ( Figure 5 , lanes D, L, P, C and H). Several independently prepared batches of RNA showed random variations in the relative amounts of dierent isoforms. The only reproducible observation was a higher level of expression of 1.6 and 2.6 kb transcripts in some cell lines from human prostate or melanoma ( Figure 5 , lanes P and C). These lines have the capacity to spread metastatically in nude mouse tumor formation assays as opposed to the others. Previous reports, using RT ± PCR assays (Bassen et al., 1999) have found a correlation with expression of isoforms containing the alternate exon encoded sequences and cellular transformation in tumor derived tissues. From results obtained by Northern blot analysis ( Figure 5 , Prostate, lane N, panels ALT1 and ALT2) it appears that normal prostate RNA apparently has a lower, but detectable level of message containing these sequences.
The two additional transcripts of 4 and 9 kb are detected by a 3' UTR probe downstream of the 3' end of the 2.6 kb transcript. Since these are not visible on a blot made with polyA RNA we believe these could represent long lived partially processed forms of the primary transcript as described above. Again, cells with metastatic capacity in nude mouse seem to contain higher levels of 9 kb transcript. At the present time the potential role of each speci®c isoform is unclear and could range from dierential stability to speci®c localization in distinct intracellular pools of untranslated message. We are in the process of characterizing rabbit polyclonal antibodies raised against PCTA-1 peptides. This reagent should aid in the clari®cation of several aspects of PCTA-1 expression described above, not in the least, the correlation between mRNA and protein expression in dierent contexts. Figure 6 summarizes the several observed and predicted isoforms of PCTA-1 message based on information from gene structure, Northern blot, RT ± PCR and EST sequence analyses.
Using live un®xed cells to determine cellular localization of GFP/PCTA-1 protein expression, we observed an essentially intracellular but extranuclear pattern of expression. This pattern was not uniformly disseminated throughout the cytosol, but showed micro-clustering reminiscent of organellar association (Bassen et al., 1999; Hadj Sahraoui et al., 1996; Lutomski et al., 1997; Maldonado et al., 1999; Maquoi et al., 1997; Sara®an et al., 1998; Su et al., 1996) . The original study with the Pro 1.5 antibody implicated a cell surface localization of the antigen . However, both Pro 1.5 and the Po-66 monoclonal antibody, which recognized an expression clone related to PCTA-1, in an independent screen, detected multiple bands in cellular protein extracts by Western blotting (Bassen et al., 1999; Su et al., 1996) . It is possible that the antibodies isolated in these immunological screens recognize additional polypeptides containing related epitopes. We cannot exclude the possibility that intracellular localization of PCTA-1 may vary depending on the physiological status of a cell, speci®c cell type, the isoform being expressed and response to extracellular signals. Puri®ed rat Galectin-8 migrates with a higher molecular weight under native conditions, interpreted as slowed migration due to association with other proteins (Hadari et al., 1995) . We are in the process of analysing potential interacting partners and intracellular localization of various isoforms of PCTA-1 to further understand its biological role through localization.
Overexpression of PCTA-1 ORF, excluding the alternative exons, in HeLa or DU145 cells caused a growth suppressive phenotype in soft agar colony forming assays. This result appears to be counterintuitive to what one would expect for a gene associated with cellular transformation. The complexity of mRNA expression pattern, probable post-transcriptional regulation via a structured 5' UTR and variations in the type of protein expressed through linker region modi®cation, seems to argue for tight regulation of PCTA-1 expression within cells. Constitutive overexpression could therefore prove deleterious to cells in speci®c contexts such as contact independent growth. This ®nding could have implications in regulation of metastatic spread of cancer cells since signi®cant growth inhibition is not observed in PCTA-1 overexpressing cells grown on normal tissue culture plasticware, only in soft agar assays. Two independent experimental strategies, one involving integration of the expression construct into genomic DNA (stable cell lines) and the other involving episomal expression (Adenovirus infected cells), showed inhibition of colony formation by full-length PCTA-1 overexpression. In addition, cell lines overexpressing a truncated version of PCTA-1, show notable levels of enhanced colony formation over control cell or those expressing the full-length ORF (30% and 70% respectively), implying that inhibition with wild-type protein is likely to be a genuine phenomenon. Overexpression of other galectins in cells or tissues have been similarly associated with opposing eects on growth, being stimulatory in some contexts (Bresalier et al., 1997; Schoeppner et al., 1995) or inducing apoptosis in others (Perillo et al., 1995; Yang et al., 1996) . One could therefore hypothesize that expression of PCTA-1 could in a speci®c setting, act as a relative growth suppressor (e.g. when expressed in LNCaP cells) but as progression of the transformed phenotype occurs, a reversal of roles could occur and PCTA-1 might act as a contributory factor in tumor progression or metastasis (e.g. in the PC-3 context).
Given the complexity of isoform expression pattern, genomic location on 1q42-43 and ubiquitous expression pattern, this member of the galectin family is likely to be an important mediator of as yet unde®ned cellular processes. The characterization of several aspects of PCTA-1 gene structure and function described above, seem to indicate that this gene could have a role to play in the transformed phenotype and tumor metastasis. This study has helped de®ne which aspects of PCTA-1 require further detailed analysis. These include distribution and phenotype induced by speci®c isoforms, changes in levels and composition of PCTA-1 as a function of transformation and systematic tissue analysis to determine any correlation with speci®c disease. Further studies are contingent on the availability of isoform speci®c reagents and are the present focus of ongoing research.
Materials and methods

Chromosomal localization
Rodent-human hybrids used in this study are available through the Human Genetic Mutant Repository (HGMCR Coriell Institute, Camden, NJ, USA) or were described previously (Feinstein et al., 1995) . Stanford and Genebridge radiation hybrid (RH) mapping panels (Cox et al., 1990; Walter et al., 1994) were purchased from Research Genetics. Primers used to amplify a 177 bp PCTA-1 product were: PCTAF, 5'-AATGGCTTCTGTGATACT-3' and PCTAR, 5'-GGCTATAAGTGTTGCTGC-3'. PCR reactions were carried out in a ®nal volume of 12.5 ml with 100 ng template, 20 ng primer, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 0.1 mg/ ml gelatin, 15 mM MgCl 2 , 200 mM dNTPs and 0.5 U Taq polymerase. Ampli®cations were performed in a Perkin-Elmer Cetus 9600 thermal cycler for 30 cycles of 948C for 30 s, 588C for 30 s and 728C for 30 s. The PCR products were visualized in ethidium bromide stained 1.5% agarose gels. The ampli®cation product of the gene was sequenced to ensure its identity.
Cell lines, tissue culture and transfection
The LNCaP, PC-3 and DU145 prostate cancer cell lines were obtained from the ATCC and maintained according to the instructions provided. The HO-1 and C8161 melanoma cell lines were cultured and maintained as previously described (Jiang et al., 1996; Su et al., 1998; Welch et al., 1994) . Transfection of cells was performed using the Superfect reagent (Qiagen) according to the supplier's instructions.
Genomic and cDNA clone analyses
A human genomic BAC library (Genome Systems Release II) was screened using a 32 P-labeled PCTA-1 ORF probe. Analysis of the isolated clones was performed by subcloning fragments in plasmid vectors and sequence analysis using plasmid or cDNA derived primers Southern blotting and PCR analyses was used to map and order the dierent regions of the gene. Sequence analysis was performed using the Fasta, Gap and Best®t subroutines in the GCG sequence analysis package (Genetics Computer Group Inc) and BLAST searches at the NCBI.
Transcriptional analyses
Total RNA was prepared using the RNAeasy kit (Qiagen) according to the supplied protocols and hybridization was performed using UltraHyb (Ambion) and the EasyStrip (Ambion) systems when the same blot was to be reprobed. Northern blot analysis was performed as described previously (Gopalkrishnan et al., 1999) and washing conditions were stringent (0.26SSC/55 ± 608C) to prevent cross hybridization of related species of RNA. RT ± PCR analyses was performed by reverse transcribing 1 mg of total cellular RNA using Superscript II (Life Technologies Inc.) at 428C for 90 min in the supplied buer, followed by one or two rounds of PCR with gene speci®c primers for 25 ± 30 cycles. Primer extension analysis was performed essentially as described previously (Gopalkrishnan et al., 1996) , except that 50 ± 75 mg total RNA was required to obtain signals for low abundance PCTA-1 mRNA. Commercial multiple tissue Northern blots were used as recommended by the manufacturer (Clontech) except that the EasyStrip system (Ambion) was used to prepare probes to enable multiple use of each blot.
Western blotting and immunofluorescence
Cells transfected with empty vector or GFP/PCTA-1 cells were harvested on ice with RIPA buer containing a protease inhibitor mix (Roche), spun at 15 000 g for 30 min at 48C and supernatant loaded in 16Laemelli dye on a 10% SDS ± PAGE, transferred by electro-blotting onto nitrocellulose membranes and probed with anti-GFP monoclonal antibody (Clontech). Cells were transfected with appropriate vectors after plating overnight on sterilized cover slips. Cells were washed three times in PBS and directly mounted in PBS on a coverslip to observe expression and localization of PCTA-1 under a¯uorescence microscope (Nikon).
Stable cell lines, soft agar colony formation assays, adenovirus transduced expression Stable cell lines were constructed using the pCDEF3 expression vector (Gopalkrishnan et al., 1999) and selecting clones with G418 followed by screening for expression by Northern blotting. Agar colony formation assays with stable expressing cell lines or adenovirus infected cells were performed essentially as described in (Jiang et al., 1996; Su et al., 1998) .
